1. Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of initiation (3,7,8,21,22,37–47).
Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of initiation (3,7,8,21,22,37–47). ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; BARI-2D, Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes and Acute Coronary Syndrome; FREEDOM-CVO, Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes; HEART-2D, Hyperglycemia and Its Effect after Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus; ORIGIN, Outcome Reduction with an Initial Glargine Intervention; SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus—Thrombolysis in Myocardial Infarction 53; VADT, Veterans Affairs Diabetes Trial. *Includes events requiring hospitalization. †Includes fatal and nonfatal events.
Nikolaus Marx et al. Dia Care 2017;40:
©2017 by American Diabetes Association